证券代码：000739 证券简称：普洛药业 公告编号：2026-11 普洛药业股份有限公司 第九届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）第九届董事会第十九次会议通知于 2026 年 3 月 8 日以电子邮件及短信的方式发出，会议于 2026 年 3 月 18 日上午通过现场会议 的方式召开，会议应到董事 9 人，实到董事 9 人。会议由公司董事长祝方猛先生主持， 公司部分高管列席了会议。本次会议的召开，符合《中华人民共和国公司法》和本公司 章程的规定。出席会议的董事经过审议表决，通过了以下议案： 一、审议通过《2025 年年度报告全文及摘要》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 本议案尚须提交公司股东会审议。 二、审议通过《2025 年度董事会工作报告》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 五、审议通过《2025 年度利润分配和资本公积金转增股本方案》 表决结果：同意票 9 票 ...

临时公告 证券代码：000739 证券简称：普洛药业 公告编号：2026-13 普洛药业股份有限公司 2025 年度利润分配和资本公积金转增股本方案 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、审议程序 2026 年 3 月 18 日，普洛药业股份有限公司（以下简称"公司"）第九届董事会第十 九次会议审议通过了《2025 年度利润分配和资本公积金转增股本方案》。 本议案尚需提交公司 2025 年年度股东会审议。 2025 年度公司中期分红 400,049,869.20 元，回购股份（以自有资金采用集中竞价方 式回购的股份) 注销总金额 153,093,045.60 元（含交易费用），2025 年度公司现金分红 和回购注销金额合计 821,109,798.48 元，占公司 2025 年度归属于上市公司股东净利润的 92.19%。 1 临时公告 本方案披露后至实施前，如公司总股本由于股份回购、股权激励行权、再融资新增股 份上市等原因发生变动，按照"每股派发现金红利不变，相应调整现金分红总额"的原则 进行调整。 三、现金分红方案的具体情况 （一）是否可能触及 ...

普洛药业股份有限公司 2025 年年度报告全文 普洛药业股份有限公司 2025 年年度报告 【2026 年 3 月 20 日】 1 普洛药业股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人祝方猛、主管会计工作负责人张进辉及会计机构负责人（会 计主管人员）石新跃声明：保证本年度报告中财务报告的真实、准确、完 整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 本报告第三节"管理层讨论与分析"中描述了公司未来经营中可能存在 的风险及应对措施，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以公司总股本 1,158,443,576 股扣减公司回购专用证券账户中股份 32,532,300 股后的股本 1,125,911,276 股为基数，向全体股东每 10 股派发现金红利 2.38 元（含 税），送红股 0 股（含税），不以 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The animal health raw material drug prices are expected to experience a cyclical rebound in 2026 due to a recovery in industry demand and stabilization of antibiotic supply chain prices [1] - The heparin raw material drug industry is currently at a cyclical low, with prices declining sharply in 2023, but expected to stabilize by 2025 [2][56] - The vitamin industry is entering a price increase cycle influenced by geopolitical tensions and rising oil prices, leading to significant price increases for vitamin A and E [3][58] Summary by Sections Raw Material Prices and Trends - The PPI index for China's chemical raw materials has been on a downward trend, while upstream raw material prices are showing an upward trend, which may accelerate the supply clearance in the raw material drug industry [11][18] - Antibiotic prices, including 6-APA and penicillin industrial salt, are showing signs of recovery after hitting bottom [25][29] - The average price of florfenicol has dropped from 400-700 RMB/kg to 150-200 RMB/kg, indicating a significant decline due to oversupply and weak downstream demand [46][49] Investment Recommendations - The report suggests focusing on companies that have undergone thorough supply clearance and have expectations for price increases, recommending stocks such as Guobang Pharmaceutical, Puluo Pharmaceutical, and Aorite [4][72] - Beneficiary stocks include Meinuo Pharmaceutical, Chuaning Biological, and Zhejiang Pharmaceutical, among others [4][72] Price Trends in Specific Segments - Heparin API prices are expected to stabilize in 2025 after a period of decline due to oversupply [56][57] - Iodine raw material prices have seen a recovery due to strong demand from other industries, following a period of significant price increases [2][56] - The vitamin A and E prices are experiencing rapid increases due to geopolitical tensions affecting oil prices and supply chain disruptions [3][58]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [2][32]. Core Insights - The pharmaceutical sector experienced a slight decline of 0.2% this week, while the Shanghai Composite Index fell by 0.7% and the Wind All A Index (excluding financials and petrochemicals) decreased by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 30.3 times earnings, ranking 12th among 31 first-level sub-industries [6][14]. - Key developments include the approval of the world's first invasive brain-computer interface in China and the release of significant clinical trial results for innovative drugs [11][16][20]. Market Performance - The pharmaceutical index ranked 13th among 31 first-level sub-industries this week [3]. - Performance across various sub-sectors includes: - Raw materials (+1.3%) - Chemical preparations (-0.8%) - Traditional Chinese medicine (-0.1%) - Blood products (+0.3%) - Vaccines (+1.3%) - Medical devices (-2.0%) - Medical consumables (+4.1%) [6][10]. Recent Key Events - Jiangsu Province has launched an action plan for the innovation and development of the brain-computer interface industry, aiming for breakthroughs in technology by 2027 [11][12]. - The global first implantable brain-computer interface by Borui Kang Medical has been approved, designed for patients with spinal cord injuries [15]. - Significant clinical trial results were published for innovative drugs, including the CSF-1R inhibitor Beijiemai and the treatment for focal onset epilepsy, Azetukalner [16][17]. Company Developments - Lizhu Pharmaceutical's acquisition of the Vietnamese company IMP has been approved, valued at approximately 1.587 billion yuan [20]. - Kanglong Chemical has entered a production cooperation agreement with Eli Lilly for the oral GLP-1 receptor agonist Orforglipron, with an expected investment of 200 million USD [22]. - New drug development activities remain active, with several companies highlighted for their innovative drug candidates [2][19]. Investment Recommendations - Investors are advised to pay attention to companies involved in raw material pharmaceuticals due to recent price increases, including Xinhui Cheng, Zhejiang Pharmaceutical, and Tianxin Pharmaceutical [2]. - Continuous monitoring of innovative drug-related companies is recommended, including Heng Rui Pharmaceutical, Bai Jie Shen Zhou, and Nuo Cheng Jian Hua [2]. - The brain-computer interface sector is also highlighted for potential investment opportunities, with companies like Aipeng Medical and Xiangyu Medical being of interest [2].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [4]. Core Insights - The company has launched a stock incentive plan for its CDMO business core management and technical staff, which is expected to drive growth. The plan involves granting 7.597 million stock options at a price of 13.38 RMB, with performance targets set for net profit growth from 2026 to 2029 [4]. - The CDMO business has become the largest revenue contributor, with a revenue of 1.69 billion RMB in the first three quarters of 2025, representing a year-over-year growth of 20%. The gross margin for this segment is 44.5%, up by 3.7 percentage points [7]. - The company anticipates a recovery in overall performance, with expected net profits of 909 million RMB in 2025, 1.052 billion RMB in 2026, and 1.233 billion RMB in 2027, reflecting a year-over-year growth of 15.76% and 17.20% in the following years [6][7]. Financial Summary - The company’s projected net profit for 2025 is 909 million RMB, with an EPS of 0.78 RMB, and a P/E ratio of 22.91. For 2026, the net profit is expected to rise to 1.052 billion RMB, with an EPS of 0.91 RMB and a P/E ratio of 19.79. By 2027, the net profit is projected to reach 1.233 billion RMB, with an EPS of 1.06 RMB and a P/E ratio of 16.89 [6][10]. - The company’s revenue is expected to increase from 10.472 billion RMB in 2025 to 11.347 billion RMB in 2026, and further to 12.047 billion RMB in 2027 [10].

Investment Rating - The report upgrades the investment rating of the company to "Buy" [4] Core Insights - The company has launched a stock incentive plan for key management and technical personnel in its CDMO business, which is expected to drive growth. The plan involves granting 7.597 million stock options, representing approximately 0.66% of the total share capital, with a grant price of 13.38 RMB per share [4] - The CDMO business has become the largest revenue contributor, with a revenue of 1.69 billion RMB in the first three quarters of 2025, showing a year-over-year growth of 20%. The gross margin for this segment is 44.5%, an increase of 3.7 percentage points [7] - The company anticipates a recovery in performance, with projected net profits of 909 million RMB, 1.052 billion RMB, and 1.233 billion RMB for 2025, 2026, and 2027 respectively, reflecting a year-over-year growth of -11.9%, +15.8%, and +17.2% [6][7] Financial Summary - The company's projected net profit for 2025 is 909 million RMB, with an EPS of 0.78 RMB, and a P/E ratio of 22.91 [6] - For 2026, the net profit is expected to rise to 1.052 billion RMB, with an EPS of 0.91 RMB, and a P/E ratio of 19.79 [6] - By 2027, the net profit is projected to reach 1.233 billion RMB, with an EPS of 1.06 RMB, and a P/E ratio of 16.89 [6]

证券简称：普洛药业 证券代码：000739 普洛药业股份有限公司 2026 年股票期权激励计划 （草案） 二〇二六年三月 普洛药业股份有限公司 2026 年股票期权激励计划（草案） 声明 本公司及全体董事保证本激励计划及其摘要的内容真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或行使权益安排的，激励对象自相关信息披 露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励计划所获 得的全部利益返还公司。 1 普洛药业股份有限公司 2026 年股票期权激励计划（草案） 特别提示 一、普洛药业股份有限公司（以下简称"公司"）2026年股票期权激励计划 （以下简称"本激励计划"）系依据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司股权激励管理办法》和其他有关法律、法规、规范性文件 以及《普洛药业股份有限公司章程》制定。 二、本激励计划采取的激励工具为股票期权。股票来源为公司向激励对象定 向发行公司A股普通股股票。 三、本激励计划拟向激励对象授予的股票期权数量为759.70万份，约占本 ...

证券简称：普洛药业 证券代码：000739 公告编号：2026-09 普洛药业股份有限公司 2026 年股票期权激励计划 （草案）摘要 二〇二六年三月 普洛药业股份有限公司 2026 年股票期权激励计划（草案）摘要 声明 本公司及全体董事保证本激励计划及其摘要的内容真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示 一、普洛药业股份有限公司（以下简称"公司"）2026年股票期权激励计划 （以下简称"本激励计划"）系依据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司股权激励管理办法》和其他有关法律、法规、规范性文件 以及《普洛药业股份有限公司章程》制定。 二、本激励计划采取的激励工具为股票期权。股票来源为公司向激励对象定 向发行公司A股普通股股票。 三、本激励计划拟向激励对象授予的股票期权数量为759.70万份，约占本激 励计划草案公告时公司股本总额115,844.3576万股的0.66%，其中，首次授予 608.40万份，约占本激励计划草案公告时公司股本总额的0.53%，首次授予部分 占本次拟授予权益总额的80.08%；预留151.30万份，约占本激励计划草案公告时 公司股本总 ...